1. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network 
Ginna G. Laport, Juan Wu, Brent Logan, Veronika Bachanova, Chitra Hosing, Timothy Fenske, Walter Longo, Steven M. Devine, Auayporn Nademanee, Iris Gersten, Mary Horowitz, Hillard M. Lazarus, Marcie L. Riches 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 8, Pages (August 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Progression-free (solid line) and overall survival (dashed line).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Cumulative incidences of relapse/progression (solid line) and nonrelapse mortality (dashed line).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3 Serum RTX concentrations over time.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
(A) Acute grades 3 and 4 GVHD incidence by day +28 serum RTX level (high versus low). (B) Overall survival by day +28 serum RTX level (high versus low).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions